Scilex Holding Co Stock Price, News & Analysis

Scilex Holding Company, trading on Nasdaq under SCLX, announced the launch of its third commercial product, GLOPERBA®, on June 10, 2024. GLOPERBA® is the first oral liquid medicine for the prophylaxis of gout flares. The product is now available in many national and independent pharmacy chains at a price of $595 per bottle.

Scilex is currently negotiating with additional pharmacy chains to expand distribution. The company emphasizes its commitment to making GLOPERBA® widely accessible across the U.S. Gout, which affects approximately 9.2 million Americans, presents a significant market opportunity, with the U.S. gout treatment market expected to reach $2.0 billion by 2028.

For more details, visit www.gloperba.com.

Scilex Holding Company (Nasdaq: SCLX) announced that the stocking of GLOPERBA®, its third commercial product, is underway in all wholesalers with which it has stocking arrangements throughout the U.S. The process is expected to complete by June 12, 2024. GLOPERBA® is the first and only liquid oral formulation of colchicine for the prophylaxis of gout flares in adults. Scilex has increased the production of GLOPERBA® and supports patients with a co-pay savings card. For more details, visit www.gloperba.com.

Scilex Holding announced FDA approval for the commercial manufacturing of Gloperba®, the first and only liquid colchicine for gout prophylaxis. Launching in the U.S. on June 10, 2024, Gloperba® targets a growing market of 9.2 million gout sufferers. The U.S. gout treatment market may reach $2 billion by 2028. Gloperba® offers flexible dosing, potentially benefiting over 70% of gout patients with comorbid conditions and 17% experiencing severe gastrointestinal side effects from other colchicine forms. Scilex's experienced team and established distribution network will support the launch.

Scilex Holding Company (Nasdaq: SCLX) has sent letters to the U.S. Securities and Exchange Commission (SEC) and the Financial Industry Regulatory Authority (FINRA) regarding illegal market manipulation of its common stock. The company alleges that manipulative practices such as 'naked short selling' are being used to devalue its stock, violating SEC Regulation SHO. Scilex Management is committed to combating these illegal activities to protect shareholder value and rights. Copies of the letters can be accessed via the provided links.

Scilex Holding Company (Nasdaq: SCLX) announced it will be added to the MSCI Global Micro Cap Index effective May 31, 2024. This inclusion is expected to enhance visibility for Scilex’s non-opioid pain management therapeutics within global financial markets. MSCI, a leading provider of research and data for investment decision support, acknowledged Scilex’s progress over the past year. The company focuses on developing and commercializing products for acute and chronic pain management and has seen strong investor interest in its innovative clinical-stage portfolio.

Scilex Holding Company (Nasdaq: SCLX) has sent a letter to the U.S. House of Representatives regarding illegal market manipulation of its common stock. The company highlights concerns over 'naked short' selling or maintaining 'naked short' positions, which may violate SEC Regulation SHO. These practices are believed to reduce shareholder value and infringe upon shareholders' rights. Scilex is committed to combating this manipulative and illegal short selling to protect its stock and shareholder interests. Further details can be accessed on Scilex's official website.

Scilex Holding Company (Nasdaq: SCLX) announced final court approval of a settlement agreement with Takeda Pharmaceuticals, resolving a patent infringement lawsuit related to Scilex's intention to expand the label for its liquid colchicine product, Gloperba®. The U.S. District Court for the District of Delaware approved the settlement, allowing Scilex a non-exclusive license to certain Takeda patents. Following this, Scilex requested the FDA convert its tentative approval of the expanded Gloperba® label to final approval.

The expanded label aims to address unmet medical needs, offering specific dosing guidance for patients with renal impairment. Market research shows high interest among rheumatologists for Gloperba®'s precision dosing capabilities. The expanded label would provide dosing flexibility and personalized adjustment options for patients, aligning with American College of Rheumatology guidelines.

Scilex Holding Company is taking steps to combat manipulative and naked short selling practices in its common stock. The company provided information to its stockholders regarding short selling activities. Scilex believes there are approximately 10 million shares being sold short and more than 10 million Dividend Shares sold as 'naked short' positions. It is determined to protect shareholder value and rights by addressing these practices.